Disease Roundup: Four Gene-Editing Candidates in...
Sep. 20, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Sanofi
Main (gene editing) focus: Blood diseases
Company stage: Commercial
Diseases: Sickle cell disease, beta-thalassemia
Genome editing tool: Zinc finger nucleases (ZFNs)
Funding stage: Public (NASDAQ:SNY)
Location: Paris, France
Website: https://www.sanofi.com/
Pipeline: https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline
Partners: Sangamo Therapeutics
Sanofi is a large pharmaceutical company that is primarily involved in the gene-editing space through its collaboration with Sangamo Therapeutics. Two programmes are being developed under the collaboration: SAR445136 and ST-400 for sikcle cell disease and beta thalassemia, respectively. Both programmes are currently being tested in Phase 1/2 clinical trials, with postive preliminary results to date.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
